GI Pancreatic - Metastatic

Localised

- NeoAdjuvant
- Adjuvant

First Line Treatment for Advanced or Metastatic Pancreatic Cancer

- IRB# 19211: A Feasibility Study to Assess a Window of Opportunity Strategy for Targeted PARP or MEK Inhibition in Patients with Pancreatic Ductal Adenocarcinoma

- IRB# 21614: NeoOptimize: An Open-Label, Phase II Trial To Assess The Efficacy Of Adaptive Switching Of mFolfirinox Or Gemcitabine/Nab-Paclitaxel As A Neoadjuvant Strategy For Patients With Resectable And Borderline Resectable Pancreatic Cancer.

- IRB# 17751: Trans(Intra)-arterial Gemcitabine vs. Continuation of IV Gemcitabine and Nab-Paclitaxel following Radiotherapy for Locally Advanced Pancreatic Cancer

- IRB# 15588: New study will be available soon.

- IRB# 17094: A Phase ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

- IRB#2316: A Phase I Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of AZD0171 in Combination with Durvalumab and Chemotherapy in Participants with Locally Advanced, Recurrent, or Metastatic Pancreatic Adenocarcinoma

- IRB#23124: A Phase Ib/2 Randomized Study of AVB-S6-500 plus Nab-paclitaxel and Gemcitabine in Patients with Locally Advanced, Recurrent, or Metastatic Pancreatic Adenocarcinoma (Morpheus-Pancreatic Cancer)

Metastatic

Second Line Treatment for Advanced or Metastatic Pancreatic Cancer

- IRB# 17094: A Phase ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

Third Line Treatment for Advanced or Metastatic Pancreatic Cancer

- IRB#15588: New study will be available soon.

Cross-Disease Trials:

- IRB# 20679: Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) Trial: Adaptive Clinical Treatment

KEY

- Open to Enrollment
- In Development
- Enrollment on Hold

https://apps.ohsu.edu/research/study-participation-opportunities-system/knight.php#result
Quality Improvement Trials:

IRB # 22619: A Phase II Trial of Pre-operative Endoscopic Botulinum Toxin Injection in the Prevention of Postoperative Pancreatic Fistula following Distal Pancreatectomy

IRB# 22413 Polyglycolic Acid Mesh to Prevent Pancreatic Fistula After Distal Pancreatectomy: A Multi-Center Efficacy Trial

https://apps.ohsu.edu/research/study-participation-opportunities-system/knight.php#result